| A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) (NCT02817633) | Tesaro, Inc. | 2016-07-08 |
| Effect of Itraconazole on the Pharmacokinetics of Apatinib (NCT02836171) | Jiangsu HengRui Medicine Co., Ltd. | 2016-07-01 |
| Integrative Parenteral Nutrition in Cancer Patients (NCT02828150) | Fondazione IRCCS Policlinico San Matteo di Pavia | 2016-07-01 |
| Intra-peritoneal Chemotherapy in Ovarian Cancer (NCT02861872) | Radboud University Medical Center | 2016-07-01 |
| Study on Neuroepithelial Tumor Grading and Pseudoprogression After Glioma Therapy Using Advanced Functional MRI Techniques (NCT02622620) | Tang-Du Hospital | 2016-07-01 |
| Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1) (NCT02723955) | GlaxoSmithKline | 2016-06-23 |
| Administration of T Lymphocytes for Prevention of Relapse of Lymphomas (NCT02663297) | UNC Lineberger Comprehensive Cancer Center | 2016-06-07 |
| Advanced Endoscopic Imaging in Colonoscopy (NCT02929381) | Miroslaw Szura | 2016-06-01 |
| Tumor-educated Platelets in Venous Thromboembolism (NCT02739867) | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 2016-06-01 |
| Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer (NCT02732327) | Forest Laboratories | 2016-05-17 |
| A Study of LY2880070 in Participants With Advanced or Metastatic Cancer (NCT02632448) | Esperas Pharma Inc. | 2016-05-16 |
| Potlako: A Programmatic Intervention to Improve Access to Timely Oncology Care (NCT02752061) | Harvard School of Public Health (HSPH) | 2016-05-13 |
| A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors (NCT02760797) | Hoffmann-La Roche | 2016-05-09 |
| A Cross-over Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics (PK) of GSK525762 in Healthy Female Subjects of Non Child Bearing Potential (NCT02706535) | GlaxoSmithKline | 2016-05-05 |
| Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001) (NCT02720068) | Merck Sharp & Dohme LLC | 2016-05-02 |
| Effect of Rifampicin on the Pharmacokinetics of Apatinib (NCT02836821) | Jiangsu HengRui Medicine Co., Ltd. | 2016-05-01 |
| Intelligent Pain Management System for Assessing Pain in Cancer Patients (NCT02765269) | Xinhua Translational Institute for Cancer Pain, Shanghai | 2016-05-01 |
| PF-06671008 Dose Escalation Study in Advanced Solid Tumors (NCT02659631) | Pfizer | 2016-04-28 |
| Dose Escalation Study of GSK2820151 in Subjects With Advanced or Recurrent Solid Tumors (NCT02630251) | GlaxoSmithKline | 2016-04-25 |
| Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer (NCT02657889) | Tesaro, Inc. | 2016-04-15 |
| Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment (NCT02696642) | Bayer | 2016-04-14 |
| Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced Solid Tumors (NCT02688101) | Collaborative Medicinal Development Pty Limited | 2016-04-11 |
| Weekly BI 836880 in Patients With Advanced Solid Tumors (NCT02689505) | Boehringer Ingelheim | 2016-04-04 |
| Pharmacokinetic Drug-Drug Interaction Study of Rucaparib (NCT02740712) | pharmaand GmbH | 2016-04-01 |
| Apixaban as Treatment of Venous Thrombosis in Patients With Cancer: The CAP Study (NCT02581176) | University Hospital, Akershus | 2016-04-01 |
| Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors (NCT02715284) | Tesaro, Inc. | 2016-03-07 |
| A Phase I Study of PLX038 in Patients With Advanced Solid Tumors (NCT02646852) | ProLynx LLC | 2016-03-01 |
| Rivaroxaban Versus Low-molecular-weight Heparin for Preventing Thrombosis in Cancer Patients (NCT03282643) | Capital Medical University | 2016-02-16 |
| Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer (NCT02635672) | Vincerx Pharma, Inc. | 2016-02-10 |
| Exercise to Prevent AnthrCycline-based Cardio-Toxicity Study (NCT02471053) | Nova Scotia Health Authority | 2016-02-01 |
| Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC) (NCT02588612) | GlaxoSmithKline | 2016-02-01 |
| Immunostimulating Interstitial Laser Thermotherapy in Solid Cancers (NCT02690428) | Clinical Laserthermia Systems AB | 2016-02-01 |
| Evaluating the Use of Wearable Biosensors and PROs to Assess Performance Status in Patients With Cancer (NCT02659358) | Cedars-Sinai Medical Center | 2016-01-24 |
| Dose Finding Study of BI 836880 in Patients With Solid Tumors (NCT02674152) | Boehringer Ingelheim | 2016-01-05 |
| Oncogeriatric Intervention and Follow-up at Home (NCT02837679) | Aarhus University Hospital | 2016-01-01 |
| Study Comparing Two Strategies of Exercise in Breast and Colon Cancer Survivors and Their Impact on Fatigue (NCT02647398) | Puerta de Hierro University Hospital | 2016-01-01 |
| Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients (NCT02526953) | Blokhin's Russian Cancer Research Center | 2016-01-01 |
| Impact of Availability of Showerpatch for Patients With Intravenous Catheters (NCT02324868) | Universitaire Ziekenhuizen KU Leuven | 2016-01-01 |
| Nordic Pole Walking for Individuals With Cancer (NCT03942614) | University of Ontario Institute of Technology | 2015-12-16 |
| Phase I Dose Escalation Study of BAY 1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors (NCT02592785) | Bayer | 2015-12-15 |
| Autologous Tumor Tissue Antigen-sensitized DC-CIK Cells Combined With Chemotherapy for Esophageal Cancer (NCT02644863) | Shenzhen Hornetcorn Bio-technology Company, LTD | 2015-12-01 |
| Utility of Plasma Circulating Tumor DNA (ctDNA) in Asymptomatic Subjects for the Detection of Neoplastic Disease (NCT02612350) | Pathway Genomics | 2015-11-01 |
| A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders (NCT02494258) | Celgene | 2015-10-22 |
| A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors (NCT02558140) | Hoffmann-La Roche | 2015-10-11 |
| Radiofrequency Ablation of Malignant Pulmonary Nodules (NCT02629978) | Chinese PLA General Hospital | 2015-10-01 |
| Sleep Quality in Patients With Advanced Cancer (NCT02585609) | Norwegian University of Science and Technology | 2015-10-01 |
| Clinical Trials of CT-guided Percutaneous Irreversible Electroporation（IRE）in the Treatment of Patients With Locally Advanced Tumors (NCT02567734) | Yueyong Xiao | 2015-10-01 |
| A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer (NCT02543645) | Celldex Therapeutics | 2015-10-01 |
| Intraoperative Imaging of Pituitary Adenomas by OTL (NCT02629549) | University of Pennsylvania | 2015-10-01 |
| A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants (NCT02555878) | Janssen Research & Development, LLC | 2015-09-11 |
| GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1) (NCT02528357) | GlaxoSmithKline | 2015-09-11 |
| Sorafenib Administered Using a High-dose, Pulsatile Regimen: a Phase I Exposure Escalation Study (NCT02636426) | Amsterdam UMC, location VUmc | 2015-09-01 |
| Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma (NCT02507583) | david andrews | 2015-09-01 |
| Lung Cancer Radiotherapy Using Realtime Dynamic Multileaf Collimator (MLC) Adaptation And Radiofrequency Tracking (NCT02514512) | Royal North Shore Hospital | 2015-09-01 |
| Exercise Intervention for LGBT Cancer Survivors (NCT02459769) | University of Rochester | 2015-08-15 |
| Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies (NCT02485119) | Bayer | 2015-08-14 |
| Phase Ib Study of Radium Ra 223 Dichloride in Combination With Paclitaxel in Cancer Subjects With Bone Lesions (NCT02442063) | Bayer | 2015-08-01 |
| Light Therapy to Increase Energy in Adolescents and Young Adults Newly Diagnosed With Solid Tumors: A Pilot Study (NCT02429063) | St. Jude Children's Research Hospital | 2015-07-17 |
| BI 894999 First in Human Dose Finding Study in Advanced Malignancies (NCT02516553) | Boehringer Ingelheim | 2015-07-08 |
| Levothyroxine Treatment for Subclinical Hypothyroidism After Head and Neck Surgery (NCT02548715) | University of Alberta | 2015-07-01 |
| Biobehavioral Intervention in Gynecologic Oncology Patients (NCT02454036) | Rachel Miller | 2015-06-01 |
| Study of PRoliferation and Apoptosis in Rectal Cancer, Predictive & Prognostic biOmarkers: Histopathology and Imaging (NCT02486094) | Royal Marsden NHS Foundation Trust | 2015-06-01 |
| An Observational Study of the Prevalence of Patients Requiring Palliative Care in French Anti-cancer Centers. (NCT02479061) | Centre Leon Berard | 2015-06-01 |
| Exercise Intervention for Cancer Survivors (NCT02348710) | Duke University | 2015-06-01 |
| Impact of a Ketogenic Diet Intervention During Radiotherapy on Body Composition (NCT02516501) | MVZ Leopoldina GmbH | 2015-06-01 |
| Brown Adipose Tissue Activity and Energy Metabolism in Cachexia (NCT02500004) | Maastricht University Medical Center | 2015-06-01 |
| Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma (NCT02490800) | Basilea Pharmaceutica | 2015-05-20 |
| Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors (NCT02423057) | National Cancer Institute (NCI) | 2015-05-18 |
| Induction Chemotherapy Followed by Chemoradiotherapy in Esophageal Cancer (NCT02403531) | Mian XI | 2015-05-01 |
| DC-CIK Combined With TACE in the Treatment of Hepatocellular Carcinoma (NCT02487017) | Shenzhen Hornetcorn Bio-technology Company, LTD | 2015-05-01 |
| Intraoperative Imaging of Pulmonary Nodules by OTL38 (NCT02602119) | University of Pennsylvania | 2015-05-01 |
| Integrated Experiential Training Program With Coaching by Nursing Students in Childhood Cancer Patients (NCT02754973) | The University of Hong Kong | 2015-05-01 |
| A Study of Tafetinib in Chinese Patients With Advanced Solid Tumor (NCT02717741) | Nanjing Yoko Biomedical Co., Ltd. | 2015-05-01 |
| A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma (NCT02386111) | Celldex Therapeutics | 2015-05-01 |
| Clinical Benefit of Genetic Biomarkers for Guiding Treatment Decisions in Oncology Drugs (NCT02458040) | Assistance Publique - Hôpitaux de Paris | 2015-05-01 |
| A Study of LY3022855 In Participants With Breast or Prostate Cancer (NCT02265536) | Eli Lilly and Company | 2015-05-01 |
| A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors (NCT02410512) | Genentech, Inc. | 2015-04-24 |
| Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 (NCT02315066) | Pfizer | 2015-04-23 |
| A Drug Utilization Study of Radium-223 in Sweden (NCT02331303) | Bayer | 2015-04-15 |
| Impact of Anesthesia Maintenance Methods on 5-year Survival After Surgery (NCT05343260) | Peking University First Hospital | 2015-04-01 |
| Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer (NCT02530411) | Velindre NHS Trust | 2015-04-01 |
| ADC-1013 First-in-Human Study (NCT02379741) | Alligator Bioscience AB | 2015-04-01 |
| Impact of Anesthesia Maintenance Methods on Long-term Survival (NCT02660411) | Peking University First Hospital | 2015-04-01 |
| Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy (NCT02330926) | Norwegian University of Science and Technology | 2015-04-01 |
| Alberta Cancer Exercise Pilot Randomized Trial (NCT02330575) | University of Alberta | 2015-04-01 |
| Myeloproliferative Neoplasms (MPNs) Patient Registry (NCT02760238) | University Health Network, Toronto | 2015-04-01 |
| Impact of Elimination or Reduction of Dietary Animal Proteins on Cancer Progression and Survival - A Pilot Study (NCT02437474) | Rosa Aspalter | 2015-04-01 |
| Roniciclib Mass Balance Study (NCT02390154) | Bayer | 2015-04-01 |
| National Swiss Sarcoma Cohort Study (NCT02775799) | Balgrist University Hospital | 2015-04-01 |
| Immuno Positron Emission Tomography Study of GSK2849330 in Subjects With Human Epidermal Growth Factor Receptor 3-Positive Solid Tumors (NCT02345174) | GlaxoSmithKline | 2015-03-19 |
| Safety, Feasibility and Cost-effectiveness of Genotype-directed Individualized Dosing of Fluoropyrimidines (NCT02324452) | The Netherlands Cancer Institute | 2015-03-01 |
| BAY1238097, First in Man (NCT02369029) | Bayer | 2015-03-01 |
| Qigong for Breast Cancer Survivors (NCT02420249) | The University of Hong Kong | 2015-03-01 |
| Self-monitoring Physical Activity With a SMARTphone Application in Cancer Patients: a Feasibility Study (SMART) (NCT02391454) | University Medical Center Groningen | 2015-02-01 |
| Exploring New Technologies to Manage Cancer Pain in the Community (NCT02341846) | University of Aberdeen | 2015-02-01 |
| Interdisciplinary Rehabilitation of Patients With Glioma During Anti-cancer Treatment (NCT02221986) | Odense University Hospital | 2015-02-01 |
| Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetics and Anti-tumor Activity of HM95573 (NCT02405065) | Hanmi Pharmaceutical Company Limited | 2015-01-12 |
| Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas (NCT02192541) | National Cancer Institute (NCI) | 2014-12-02 |
| Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients (NCT02307487) | UroGen Pharma Ltd. | 2014-12-01 |
| Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer (NCT02215096) | GlaxoSmithKline | 2014-11-13 |